Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06045221 · ClinicalTrials.gov registry record · Phase 3
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,698
- Enrollment target
NCT06045221: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT06045221 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,698 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (120% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06045221, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,698 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61 weeks.
Interventions
- DRUG Orforglipron
- DRUG Semaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,698 participants |
| Start Date | 2023-09-22 |
| Est. Completion | 2025-08-22 |
| Phase | Phase 3 |
What the finished NCT06045221 record still lists
NCT06045221 is an interventional study that assigns participants to a tested intervention. Its 1,698 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (120% higher).
The record links to 0 conditions, and to 2 interventions - of which Orforglipron is the first listed.
NCT06045221 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06045221 about?
NCT06045221 is a clinical study titled "A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin". The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61 weeks.
What is the current status of trial NCT06045221?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,698 participants. The study started on 2023-09-22. Estimated completion is 2025-08-22.
What interventions are being tested in trial NCT06045221?
The interventions under investigation include: Orforglipron (DRUG), Semaglutide (DRUG).
Who is sponsoring clinical trial NCT06045221?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06045221's enrollment target sits among peer trials
1,698 134th of 2000 higher than 1,867 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04321200 · 1,700 participants
PANDA Gym: Automated Assessment of Neurodevelopment in Infants at Risk for Motor Disability
- NCT06238622 · 1,700 participants · Phase 3
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- NCT07284901 · 1,700 participants · Phase 3
Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- NCT07304531 · 1,705 participants
First To Know Pregnancy Test - Clinical Evaluation Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI